{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the low number of participants who died.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to the low number of participants who died.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"OS was measured as the time in months from the first dose of study treatment to the date of death + 1 day.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone"},{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once, on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once, on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Includes 3 participants who received 2.23 mg/m\\^2 in Phase 1.","id":"OG001","title":"Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Safety Population included al participants who received 1 of the 3 study drugs. Participants who did not die were censored at the last study visit.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment to the date of death (up to 787 days)","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"participants"}